Compound Monograph
Pennogenin
Pennogenin is diosgenin with one extra hydroxyl, and that single group changes what the molecule does. Its glycosides are platelet agonists — a genuinely unusual pharmacology, and the reason Paris polyphylla is a Chinese haemostatic. The same scaffold sits in beth root, the herb Western practice calls birthroot and used for bleeding.
Sources · 6
Where Does It Come From?
Pennogenin is a naturally occurring steroidal sapogenin (spirostanol aglycone; (25r)-spirost-5-ene-3β,17α-diol), found in Beth root, Western trillium, Lady of the night and 3 other sources. It is flagged as moderately toxic.
Concentration
Content by Source
Concentrations not reported. No percent-dry-weight or mg/g figures have been published for this compound in its source plants.
Pennogenin at a Glance
Pennogenin is diosgenin with one extra hydroxyl group, at carbon 17. Formally it is (25R)-spirost-5-ene-3β,17α-diol, against diosgenin’s (25R)-spirost-5-en-3β-ol — C₂₇H₄₂O₄ where diosgenin is C₂₇H₄₂O₃.
Both are spirostanol sapogenins, both sit at the centre of a large family of steroidal saponins, and both occur in the same plants. They are routinely discussed as interchangeable scaffolds. They are not, and the difference is the reason this molecule is worth its own page.
Diosgenin’s fame is industrial and largely historical — the feedstock for the first semi-synthetic steroid hormones, and the source of the durable and false belief that wild yam converts to progesterone in the body. Pennogenin has none of that history.
★ What it has instead is a pharmacology diosgenin does not share: its glycosides are platelet agonists. In a bioassay-guided separation of the haemostatic saponins of Paris polyphylla var. yunnanensis, four pennogenin glycosides turned out to be the active ingredients — promoting haemostasis in living animals and directly aggregating rat and human platelets in vitro. The authors describe them as a new type of platelet agonist 1Reference 1In vitroPennogenin glycosides with a spirostanol structure are strong platelet agonists: structural requirement for activity and mode of platelet agonist synergism — in vitro and animalView study →.
That is an uncommon thing for a plant molecule to do. Most botanical effects on platelets run the other way.
Why the Extra Hydroxyl Matters
The structure–activity work is unusually clean, and it is the whole argument for treating pennogenin as a separate molecule rather than a diosgenin variant.
Both halves are required. The aggregatory activity needs the pennogenin aglycone and the sugar chain — remove either and it goes 1Reference 1In vitroPennogenin glycosides with a spirostanol structure are strong platelet agonists: structural requirement for activity and mode of platelet agonist synergism — in vitro and animalView study →. So this is not a general property of steroidal saponins, and it is not a property of the free sapogenin on its own. It belongs to the specific combination.
The spirostanol configuration is part of the requirement, which is why the finding is expressed as pennogenin glycosides with a spirostanol structure rather than as Paris saponins 1Reference 1In vitroPennogenin glycosides with a spirostanol structure are strong platelet agonists: structural requirement for activity and mode of platelet agonist synergism — in vitro and animalView study →. Related scaffolds in the same rhizome do not do it.
A 2026 survey extended the series. Oxidised and hydroxylated pennogenin saponins isolated from Paris fargesii rhizomes were assayed for the same activity, adding structural variants to a scaffold whose haemostatic behaviour is now the best-characterised thing about it 3Reference 3In vitroOxidised- and hydroxylated-pennogenin saponins from the rhizomes of Paris fargesii and their haemostatic activity — in vitroView study →.
The Traditional Loop
Pennogenin is one of the tidier cases of a traditional use and a molecular mechanism pointing at each other.
Paris polyphylla — chonglou, Rhizoma Paridis — is a Chinese haemostatic, and it is the plant the platelet work was done on. The saponins responsible turned out to be pennogenin glycosides 1,
Beth root carries the same scaffold 9Reference 9Steroidal saponins from the roots of Trillium erectum (beth root) — phytochemistryView study →, and Western practice calls it birthroot — a herb given for postpartum and uterine bleeding. Nobody connected the two literatures; they were arrived at independently, in different centuries, on different continents.
That is a reason to take the traditional indication seriously, and equally a reason for caution. A plant whose saponins activate platelets is not a neutral thing to take alongside anticoagulant or antiplatelet medication, and no study has looked.
What It's Used For
The pharmacology of pennogenin is the pharmacology of its glycosides. The free sapogenin is barely studied in isolation, and almost nothing in the literature tests it on its own — which is chemically reasonable, since the plant does not accumulate it in free form either.
The evidence divides into three unequal parts: a well-developed platelet-agonist story with an in-vivo endpoint, a small recent metabolic literature on one particular glycoside, and the usual scatter of cell-line cytotoxicity that follows any steroidal saponin.
No human trial has been conducted on pennogenin or any pennogenin glycoside, and none is registered.
This is the finding that makes pennogenin a distinct molecule rather than a diosgenin footnote.
Total steroidal saponins from Paris polyphylla var. yunnanensis promoted haemostasis in vivo — shortening tail bleeding time in mice and rats — and dose-dependently aggregated both rat and human platelets in vitro. Bioassay-guided separation identified four pennogenin glycosides with a spirostanol structure as the active ingredients 1Reference 1In vitroPennogenin glycosides with a spirostanol structure are strong platelet agonists: structural requirement for activity and mode of platelet agonist synergism — in vitro and animalView study →.
The mechanism was dissected in full. Aggregation involved αIIbβ3 activation, was inhibited by cAMP, and required extracellular calcium, secreted ADP and thromboxane synthesis, with signalling through PI3K. The glycosides also acted synergistically with known platelet agonists — the behaviour of an agonist rather than a sensitiser 1Reference 1In vitroPennogenin glycosides with a spirostanol structure are strong platelet agonists: structural requirement for activity and mode of platelet agonist synergism — in vitro and animalView study →.
A follow-up on pennogenin tetraglycoside confirmed direct platelet activation and pinned the dependence more precisely: antagonists of the platelet ADP receptors P2Y1 and P2Y12 completely abolished the aggregation, and dense-granule secretion was the step it ran through 2Reference 2AnimalPennogenin tetraglycoside stimulates secretion-dependent activation of rat platelets: evidence for critical roles of adenosine diphosphate receptor signal pathways — animalView study →.
Gap: all of this is rodent and in-vitro. No human haemostasis study exists, and the mechanistic caution it implies — additive effect with a prothrombotic state, opposition to antiplatelet drugs — has never been tested in a person.
A small, recent and reasonably coherent literature on a single glycoside.
Pennogenin 3-O-β-chacotrioside improved glucose handling in insulin-resistant hepatocytes: it raised insulin sensitivity and glucose uptake by activating IRS/PI3K/Akt signalling, with an accompanying increase in mitochondrial oxidative respiration 4Reference 4In vitroImprovement of glucose metabolism by pennogenin 3-O-β-chacotrioside via activation of IRS/PI3K/Akt signalling and mitochondrial respiration in insulin-resistant hepatocytes — in vitroView study →. The same compound reduced hypertrophied lipid accumulation in adipocytes, again by enhancing mitochondrial oxidative capacity 5Reference 5In vitroPennogenin 3-O-β-chacotrioside attenuates hypertrophied lipid accumulation by enhancing mitochondrial oxidative capacity — in vitroView study →.
Two studies, one molecule, one laboratory group, cells only. The consistency between them is the reason to note it at all.
Gap: no animal model, no human data, and no evidence that the parent plant delivers a meaningful amount of this particular glycoside to anything.
The usual steroidal-saponin picture: real cytotoxicity in culture, no in-vivo or human work behind it.
Pennogenin steroidal saponins from Paris polyphylla var. yunnanensis were cytotoxic to tumour cell lines in vitro 7Reference 7In vitroIn-vitro antitumour and antifungal activity of pennogenin steroidal saponins from Paris polyphylla var. yunnanensis — in vitroView study →. Spiroconazol A, a pennogenin triglycoside isolated from Dioscorea bulbifera var. sativa, induced autophagic cell death in non-small-cell lung cancer cells through p38 MAPK activation — the one report with a defined mechanism 10Reference 10In vitroSpiroconazol A, a pennogenin glycoside from Dioscorea bulbifera var. sativa, induces autophagic cell death by p38 MAPK activation in NSCLC cells — in vitroView study →.
Gap: cell lines at concentrations that say nothing about achievable exposure, and in several reports the material tested is a mixed saponin fraction rather than a characterised molecule.
Pennogenin saponins carry antifungal activity alongside their cytotoxicity in the Paris polyphylla work 7Reference 7In vitroIn-vitro antitumour and antifungal activity of pennogenin steroidal saponins from Paris polyphylla var. yunnanensis — in vitroView study →.
The cleaner result comes from a different plant. A pennogenin tetraglycoside was isolated from lady of the night (Cestrum nocturnum) by antifungal assay-guided fractionation, active against Fusarium kuroshium, the causal agent of Fusarium dieback 8Reference 8In vitroIsolation and identification of pennogenin tetraglycoside from Cestrum nocturnum and its antifungal activity against Fusarium kuroshium — in vitroView study →. That design matters: it ties the plant’s antifungal activity to this saponin class rather than to anything else in the extract.
Gap: agricultural plate assays against a crop pathogen. Nothing here bears on human fungal infection.
Mechanisms
The platelet mechanism is the only one worked out to receptor level, and it is worth reading as a whole. Pennogenin glycosides do not sensitise platelets to other agonists — they activate them directly, through the same final common pathway that ADP and thromboxane use, and the P2Y1/P2Y12 antagonist result shows secreted ADP is doing much of the work rather than a novel receptor.
The metabolic and cytotoxic rows are unconnected to it, and to each other.
| Mechanism | Drives | Key compounds |
|---|---|---|
| αIIbβ3 activation; dense-granule and ADP secretion; thromboxane synthesis; PI3K signalling 1, | haemostaticplatelet aggregation | pennogenin glycosides (spirostanol), pennogenin tetraglycoside |
| P2Y1 / P2Y12 dependence — blockade abolishes aggregation 2Reference 2AnimalPennogenin tetraglycoside stimulates secretion-dependent activation of rat platelets: evidence for critical roles of adenosine diphosphate receptor signal pathways — animalView study → | the step the above runs through | pennogenin tetraglycoside |
| IRS/PI3K/Akt activation; mitochondrial oxidative capacity ↑ 4, | insulin sensitivitylipid handling | pennogenin 3-O-β-chacotrioside |
| p38 MAPK-dependent autophagic cell death 10Reference 10In vitroSpiroconazol A, a pennogenin glycoside from Dioscorea bulbifera var. sativa, induces autophagic cell death by p38 MAPK activation in NSCLC cells — in vitroView study → | anticancer (cell line) | spiroconazol A |
Clinical Trials
None. No completed or registered trial uses pennogenin or a pennogenin glycoside for any indication.
| Completed | Planned | Terminated | Preclinical |
|---|---|---|---|
| 0 | 0 | 0 | ~10 |
Last checked: literature to 2026.
Isolate vs. Plant Studies
This distinction is unusually load-bearing here, and it runs the opposite way from most compound pages.
The isolate work is the stronger evidence. The platelet finding came from bioassay-guided separation of a plant extract down to four defined molecules, with the structure–activity relationship then established directly 1Reference 1In vitroPennogenin glycosides with a spirostanol structure are strong platelet agonists: structural requirement for activity and mode of platelet agonist synergism — in vitro and animalView study →. That is a cleaner chain than most botanical pharmacology manages.
But no plant delivers free pennogenin. It exists in the rhizome as glycosides, it is measured after hydrolysis, and every biological result belongs to a glycoside. A “pennogenin content” figure describes a scaffold recovered from a saponin mixture, not a molecule the plant contains as such — exactly as with diosgenin.
And the herbs are not equivalent. Paris polyphylla is where the pharmacology was done. Beth root and western trillium carry the same aglycone 9Reference 9Steroidal saponins from the roots of Trillium erectum (beth root) — phytochemistryView study →, but no Trillium species has been tested for platelet activity, and reading the Paris result onto them is genus-level extrapolation across two different genera.
Prevalence in Nature
Pennogenin is a Melanthiaceae and Dioscoreaceae molecule, concentrated in the rhizomes where those families store their steroidal saponins.
Its principal medicinal source is Paris polyphylla var. yunnanensis, the Chinese chonglou, where the pennogenin-bearing saponins are the marker constituents. Paris fargesii carries oxidised and hydroxylated variants of the same scaffold 3Reference 3In vitroOxidised- and hydroxylated-pennogenin saponins from the rhizomes of Paris fargesii and their haemostatic activity — in vitroView study →.
In North America it occurs in Trillium — reported from beth root roots since the 1940s and confirmed as the aglycone of several of the cytotoxic glycosides isolated from that species 9Reference 9Steroidal saponins from the roots of Trillium erectum (beth root) — phytochemistryView study →.
It also turns up outside those families: in Dioscorea bulbifera var. sativa as spiroconazol A 10Reference 10In vitroSpiroconazol A, a pennogenin glycoside from Dioscorea bulbifera var. sativa, induces autophagic cell death by p38 MAPK activation in NSCLC cells — in vitroView study →, and in the Solanaceous lady of the night as a tetraglycoside 8Reference 8In vitroIsolation and identification of pennogenin tetraglycoside from Cestrum nocturnum and its antifungal activity against Fusarium kuroshium — in vitroView study →.
Discovery & Synthesis
Pennogenin appears in the 1940s literature on Trillium erectum alongside kryptogenin, trillogenin, nologenin and bethogenin — a group of sapogenins reported from the root whose structures and glycosylation were never properly resolved. Pennogenin is the one that survived that period with a settled structure.
Its modern identity dates from 2008, when the haemostatic saponins of Paris polyphylla were separated by bioassay and the pennogenin glycosides identified as the actives 1Reference 1In vitroPennogenin glycosides with a spirostanol structure are strong platelet agonists: structural requirement for activity and mode of platelet agonist synergism — in vitro and animalView study →. Everything known about what this molecule does follows from that paper.
The biosynthesis was solved in 2026. Pennogenin synthases were identified in Paris polyphylla, and the work is interesting beyond this molecule: it showed enzyme plasticity underlying paralog evolution — how the C-17 hydroxylation that separates pennogenin from diosgenin arose and is controlled 6Reference 6Identification of pennogenin synthases in Paris polyphylla reveals enzyme plasticity underlying paralog evolution — biosynthesisView study →. That is now the cleanest statement of what makes the two molecules different, in the plant rather than on paper.
Toxicity & Safety
- Its glycosides activate platelets. This is the molecule’s best-established property, and it is a pharmacological effect on clotting rather than an incidental one 1,
2Reference 1In vitroPennogenin glycosides with a spirostanol structure are strong platelet agonists: structural requirement for activity and mode of platelet agonist synergism — in vitro and animalView study →Reference 2AnimalPennogenin tetraglycoside stimulates secretion-dependent activation of rat platelets: evidence for critical roles of adenosine diphosphate receptor signal pathways — animalView study → . - A mechanistic bleeding-and-clotting caution follows from that, in both directions — opposition to antiplatelet and anticoagulant drugs, and an additive effect in anyone already prothrombotic. Neither has been studied.
- Steroidal saponins are membrane-active and haemolytic as a class, which is a general property of the group rather than a finding specific to pennogenin.
- No toxicity signal at culinary or ordinary preparation strength has been reported for the source plants, though that reflects the absence of study as much as anything.
- No human data of any kind. No trial, no case report, no pharmacokinetics, no reproductive study.
Full Safety & Interactions Detail
The platelet effect is the safety story, and it is unusual enough to state plainly. Most botanical constituents that touch platelets inhibit them — garlic, ginkgo, the salicylates. Pennogenin glycosides do the opposite: they are direct agonists, aggregating human platelets in vitro and shortening bleeding time in two rodent species 1,
That has two consequences, and neither has been tested in a person. Against a prescribed antiplatelet or anticoagulant, the effect works in opposition to the drug. In anyone with an existing thrombotic risk, it works with it. Both are mechanism-based inferences from good preclinical work, which is a reason for care rather than a reason to discount them.
The plants this molecule comes from are used for bleeding, which is coherent with the mechanism — but a haemostatic effect and a thrombotic risk are the same pharmacology seen from two sides.
What was not assessed. There is no toxicology programme for pennogenin, no pharmacokinetic data, no CYP450 work, and no reproductive-safety study. The free sapogenin has essentially not been tested in isolation at all — the toxicological unit here, as the pharmacological one, is the glycoside.
Dosage
No human dose exists, and none should be inferred from the figures below.
Every quantity in the pennogenin literature is either an in-vitro aggregation concentration or a rodent experimental dose, and both belong to specific glycosides rather than to the sapogenin. The source plants are dosed as whole-rhizome preparations standardised — where they are standardised at all — on total steroidal saponins, not on this molecule.
No conversion between a saponin-standardised plant preparation and a pennogenin quantity is possible, and none is offered.
References
- Fu, Y. L., Yu, Z. Y., Tang, X. M., et al. (2008). Pennogenin glycosides with a spirostanol structure are strong platelet agonists: structural requirement for activity and mode of platelet agonist synergism — in vitro and animal. Journal of Thrombosis and Haemostasis. https://pubmed.ncbi.nlm.nih.gov/18182034/
- Cong, Y., Liu, X., Kang, L., et al. (2012). Pennogenin tetraglycoside stimulates secretion-dependent activation of rat platelets: evidence for critical roles of adenosine diphosphate receptor signal pathways — animal. Thrombosis Research. https://pubmed.ncbi.nlm.nih.gov/22401797/
- Yu, L. L., Jiao, L., Li, Y. X., et al. (2026). Oxidised- and hydroxylated-pennogenin saponins from the rhizomes of Paris fargesii and their haemostatic activity — in vitro. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/41371565/
- Lee, J. I., Lee, H. M., Park, J. H., et al. (2025). Improvement of glucose metabolism by pennogenin 3-O-β-chacotrioside via activation of IRS/PI3K/Akt signalling and mitochondrial respiration in insulin-resistant hepatocytes — in vitro. Molecular Nutrition & Food Research. https://pubmed.ncbi.nlm.nih.gov/40103416/
- Yu, S., Lee, H. M., Lee, J., et al. (2024). Pennogenin 3-O-β-chacotrioside attenuates hypertrophied lipid accumulation by enhancing mitochondrial oxidative capacity — in vitro. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/38474216/
- Li, S., Liao, J., Zhang, J., et al. (2026). Identification of pennogenin synthases in Paris polyphylla reveals enzyme plasticity underlying paralog evolution — biosynthesis. Molecular Plant. https://pubmed.ncbi.nlm.nih.gov/42050933/
- Zhu, L., Tan, J., Wang, B., et al. (2011). In-vitro antitumour and antifungal activity of pennogenin steroidal saponins from Paris polyphylla var. yunnanensis — in vitro. Iranian Journal of Pharmaceutical Research. https://pubmed.ncbi.nlm.nih.gov/24250355/
- Valencia-Mejía, E., León-Wilchez, Y. Y., Monribot-Villanueva, J. L., et al. (2022). Isolation and identification of pennogenin tetraglycoside from Cestrum nocturnum and its antifungal activity against Fusarium kuroshium — in vitro. Molecules. https://pubmed.ncbi.nlm.nih.gov/35335224/
- Hayes, P. Y., Lehmann, R., Penman, K., et al. (2009). Steroidal saponins from the roots of Trillium erectum (beth root) — phytochemistry. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/19091359/
- Ki, Y. S., Chung, K. S., Lee, H. W., et al. (2022). Spiroconazol A, a pennogenin glycoside from Dioscorea bulbifera var. sativa, induces autophagic cell death by p38 MAPK activation in NSCLC cells — in vitro. Pharmaceuticals. https://pubmed.ncbi.nlm.nih.gov/35890190/
